

Credo Global Cell

**Supplementary Information,
Annual Report and Audited Financial Statements for**

**Credo Global Equity Fund IC Limited
("Credo Global Cell")**

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Supplementary Information

	30.06.18	30.06.17
1. NUMBER OF SHARES OUTSTANDING		
Class A	4,779,827	6,449,819
Class B	17,924,001	18,960,093
2. NET ASSET VALUE PER SHARE - GBP		
Class A	1.43	1.38
Class B	1.03	0.99
3. HIGHEST/LOWEST PRICE - GBP*		
Class A	1.45 / 1.28	1.41 / 1.18
Class B	1.04 / 0.92	1.01 / 0.85
4. NUMBER OF SHARES SUBSCRIBED		
Class A	171,883	3,924,443
Class B	1,207,862	8,309,526
5. NUMBER OF SHARES REDEEMED		
Class A	1,841,875	76,724
Class B	2,243,954	404,107

*The highest/lowest price is based on prices from prior year-end to current year-end, being the 30.06.2018. The NAV on the 30.06.2018 was specifically calculated for financial reporting purposes and therefore may differ slightly from the most recent published price at that time.

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Portfolio Statement

	Holdings	Fair Value	% of Net Assets
	30.06.18	30.06.18	30.06.18
		<u>GBP</u>	
Financial assets at fair value through profit or loss			
Equities: 96.17% (2017: 98.07%)			
Agriculture			
British American Tobacco	25,264	967,611	3.82
Total Agriculture		<u>967,611</u>	<u>3.82</u>
Communications			
Verizon Communications	21,869	833,349	3.29
Walt Disney	11,169	886,668	3.50
Total Communications		<u>1,720,017</u>	<u>6.79</u>
Consumer, Cyclical			
Chipotle Mexican Grill	2,393	781,874	3.09
Cineworld	154,310	409,848	1.62
Crown Resorts	111,311	840,954	3.32
Genting Singapore	345,776	234,338	0.93
GVC	111,922	1,176,300	4.64
Ladbrokes Coral Rights	634,844	72,118	0.28
Las Vegas Sands	4,081	236,035	0.93
Merlin Entertainments	151,574	586,137	2.31
Paddy Power Betfair	13,155	1,091,865	4.31
Tempur Sealy International Class I	7,649	278,382	1.10
Whitbread	6,012	238,015	0.94
Total Consumer, Cyclical		<u>5,945,866</u>	<u>23.47</u>
Consumer, Non-cyclical			
Adtalem Global Education	7,366	268,362	1.06
Bectel	115,000	127,317	0.50
Cigna	4,270	549,659	2.17
Dignity	28,781	289,537	1.14
Express Scripts	19,423	1,135,883	4.49
GlaxoSmithKline	12,406	189,787	0.75
HCA Healthcare	15,276	1,187,137	4.69
Imperial Brands	38,519	1,087,006	4.29
Nielsen	11,694	273,960	1.08
PepsiCo	7,342	605,433	2.39
Spire Healthcare	341,319	855,345	3.38
Total Consumer, Non-cyclical		<u>6,569,426</u>	<u>25.94</u>

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Portfolio Statement (continued)

	Holdings	Fair Value	% of Net Assets
	30.06.18	30.06.18	30.06.18
		<u>GBP</u>	
Financial			
AIA	144,400	956,351	3.78
Arch Capital	45,771	917,327	3.62
Chubb	11,040	1,062,148	4.19
Prudential	58,971	1,022,852	4.04
Wells Fargo	28,504	1,196,941	4.73
Total Financial		<u>5,155,619</u>	<u>20.36</u>
Industrial			
Meggitt	52,167	257,340	1.02
United Parcel Service Class B	9,781	786,999	3.11
United Technologies	9,432	893,227	3.53
Total Industrial		<u>1,937,566</u>	<u>7.66</u>
Energy			
BP	106,469	615,710	2.43
Total Energy		<u>615,710</u>	<u>2.43</u>
Technology			
Microsoft	4,513	337,078	1.33
Oracle	33,102	1,104,695	4.37
Total Technology		<u>1,441,773</u>	<u>5.70</u>
Total Equities		<u>24,353,588</u>	<u>96.17</u>
Financial assets at fair value through profit or loss (2017: USD27,129,195; 98.07%)		24,353,588	96.17
Other Net Assets: 3.83% (2017: USD527,728; 1.93%)		970,453	3.83
Net Assets Attributable to Holders of Participating Redeemable Shares		<u><u>25,324,041</u></u>	<u><u>100.00</u></u>

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements as at 30 June 2018

Credo Global Cell

Statement of Financial Position

	Notes	30.06.18 <u>GBP</u>	30.06.17 <u>GBP</u>
ASSETS			
NON-CURRENT ASSETS			
Financial assets at fair value through profit or loss	5	24,353,588	27,129,195
CURRENT ASSETS			
Cash and cash equivalents	6	1,108,761	814,707
Dividend receivable		27,631	118,120
Other receivables	8	552	523
		<u>1,136,944</u>	<u>933,350</u>
Total assets		<u>25,490,532</u>	<u>28,062,545</u>
LIABILITIES			
CURRENT LIABILITIES			
Fair value of derivative financial instruments	7	-	21
Bank overdraft	6	-	93,187
Securities purchased payable		129,334	274,298
Other payables	9	37,092	38,051
Liabilities (excluding net assets attributable to holders of participating redeemable shares)		<u>166,426</u>	<u>405,557</u>
Net assets attributable to holders of participating redeemable shares	2 & 11	<u>25,324,041</u>	<u>27,656,923</u>
Total liabilities		<u>25,490,467</u>	<u>28,062,480</u>
SHAREHOLDERS' EQUITY			
Management shares	10	65	65
Total equity		<u>65</u>	<u>65</u>
Total equity and liabilities		<u>25,490,532</u>	<u>28,062,545</u>
Net asset value per participating redeemable share			
Class A	11	1.43	1.38
Class B		1.03	0.99

The notes 1 to 16 on pages 216 to 222 form part of these financial statements.

These financial statements were authorised for issue by the Board of Directors on 5 December 2018 and signed on its behalf by:



Director



Director

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018
Credo Global Cell
Statement of Comprehensive Income

		For the year ended 30.06.18	For the year ended 30.06.17
	Notes	<u>GBP</u>	<u>GBP</u>
INCOME			
Dividend income		673,402	558,335
Net realised gains on financial assets at fair value through profit or loss	5	1,945,720	1,963,865
Net unrealised (losses)/gains on financial assets at fair value through profit or loss	5	(1,272,547)	1,048,644
Net losses on forward currency contracts		(3,855)	(3,981)
Other foreign exchange gains/(losses)		16,207	(10,054)
Total net income		<u>1,358,927</u>	<u>3,556,809</u>
EXPENSES			
Audit fee		(9,783)	(9,597)
Custodian fee	13	(6,719)	(13,319)
Investment Management fee	13	(217,418)	(182,953)
Management and Administration fee	13	(73,627)	(69,320)
Interest paid		(617)	(307)
Sundry expenses		(16,600)	(14,146)
Total operating expenses		<u>(324,764)</u>	<u>(289,642)</u>
Net profit before tax		1,034,163	3,267,167
Withholding tax		(68,043)	(65,379)
Increase in net assets attributable to holders of participating redeemable shares from operations		<u>966,120</u>	<u>3,201,788</u>

All items in the above statement derive from continuing operations. There is no difference between the increase in net assets attributable to holders of participating redeemable shares and comprehensive income.

The notes 1 to 16 on pages 216 to 222 form part of these financial statements.

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018
Credo Global Cell
Statement of Cash flows

	For the year ended 30.06.18	For the year ended 30.06.17
	GBP	GBP
CASH FLOW FROM OPERATING ACTIVITIES		
Increase in net assets attributable to holders of participating redeemable shares from operations	966,120	3,201,788
ADJUSTMENT FOR:		
Net realised gains on financial assets at fair value through profit or loss	(1,945,720)	(1,963,865)
Net unrealised losses/(gains) on financial assets at fair value through profit or loss	1,272,547	(1,048,644)
Other foreign exchange (gains)/losses	(16,228)	10,075
Dividend income	(673,402)	(558,335)
Interest paid	617	307
Withholding tax	68,043	65,379
Operating loss before working capital changes	(328,023)	(293,295)
Net (increase)/decrease in other receivables	(29)	11,143
Net (decrease)/increase in other payables	(959)	16,373
Purchase of financial assets at fair value through profit or loss	(24,795,384)	(27,879,397)
Sale of financial assets at fair value through profit or loss	28,099,200	15,423,630
Interest paid	(617)	(307)
Dividends received	695,848	379,721
Net cash generated from/(used in) operating activities	3,670,036	(12,342,132)
CASH FLOW FROM FINANCING ACTIVITIES		
Cash received from issuance of participating redeemable shares	1,422,080	12,756,745
Cash paid on redemption of participating redeemable shares	(4,721,082)	(477,871)
Net cash (used in)/generated from financing activities	(3,299,002)	12,278,874
Net increase/(decrease) in cash and cash equivalents	371,034	(63,258)
Cash and cash equivalents at the start of the year	721,520	794,832
Exchange gains/(losses) on cash and cash equivalents	16,207	(10,054)
Cash and cash equivalents at the end of the year	1,108,761	721,520

The notes 1 to 16 on pages 216 to 222 form part of these financial statements.

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares

	Notes	For the year ended 30.06.18 <u>GBP</u>	For the year ended 30.06.17 <u>GBP</u>
Net assets attributable to holders of participating redeemable shares at the beginning of the year		27,656,923	12,176,261
Proceeds from issuance of participating redeemable shares	10	1,422,080	12,756,745
Payments on redemption of participating redeemable shares	10	(4,721,082)	(477,871)
Increase in net assets attributable to holders of participating redeemable shares from operations		966,120	3,201,788
Net assets attributable to holders of participating redeemable shares at the end of the year	11	<u><u>25,324,041</u></u>	<u><u>27,656,923</u></u>

The notes 1 to 16 on pages 216 to 222 form part of these financial statements.

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Notes to the Financial Statements

1. General Information

The Credo Global Equity Fund IC Limited (the "Cell"), with company number 60876, is a Guernsey registered, Limited Liability Incorporated Cell of the Momentum Mutual Fund ICC Limited (the "Company").

The Cell holds a diversified portfolio of global equities, which is believed to be well positioned to outperform the wider equity market over the longer term. The portfolio of the Cell has a bias towards developed market and large capitalisation stocks.

The Cell aims to generate sustainable excess returns versus global market indices through careful stock selection. The Cell is ideally suited to investors with a high risk tolerance with an investment time horizon of 5 years or longer.

The Cell intends to achieve its investment objective by maintaining a diversified exposure across most major global industries in order to avoid concentration in any specific themes and to allow a zero weighting to any given sector when it is believed that the longer term outlook for an industry happens to be negative.

The Cell's investment activities are managed by Momentum Wealth International Limited (the "Manager"), with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager"), and Credo Capital Plc acting as the Sub-Investment Manager.

On 9 August 2017, amendments were made to the Supplemental Cell Prospectus of the Cell, implementing the following change with effect from that date:

- An additional paragraph on page 2 of the Supplemental Cell Prospectus to clarify that where Participating Shares are promoted to retail investors in the United Kingdom by a Financial Conduct Authority ("FCA") authorised person, that person may only promote such Participating Shares to certified high net worth investors, certified sophisticated investors and self-certified sophisticated investors as those terms are defined at Part 4.12 of the FCA's Conduct of Business Sourcebook;
- Comprehensive changes to the existing investment policy;
- The Fund will not be permitted to enter into any form of borrowing or loan arrangement with other funds of the Company nor other collective investment schemes of the Manager;
- Confirmation that the minimum Investment Management fee, excludes the Sub-Investment Management Fee and relates to the net portion of Investment Management Fee of 0.10% only;
- The top tier of the Investment Management Fee's sliding scale will be reduced by 0.05%, reducing the first GBP 20 million from 0.90% to 0.85%;
- The top tier of the Management and Administration Fee's sliding scale will be reduced by 0.05% reducing the first GBP 20 million from 0.35% to 0.30%;
- The Fund is FSB approved, and this has been confirmed by the addition of section J. "Regulatory Positions"; and
- The Fund has been granted UK reporting fund status and section L. "Additional Tax Considerations" has been added in this regard.

The Financial Statements were authorised for issue by the Board of Directors on 5 December 2018.

2. Financial risk management

2.1 Strategy in using financial instruments

The Cell's activities and investment objectives expose it to a variety of financial risks: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk. The Cell's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance. The following policies and procedures to mitigate risk have been in place throughout the year.

2.2 Market price risk

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in equities. Through its investment in traded securities and instruments the Cell is subject to market movements in equity and bond markets.

All investments present a risk of loss of capital. The Investment Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. The Cell's overall market positions are monitored by the Investment Manager and are reviewed by the Board of Directors.

The Cell's market price risk is managed through diversification of the investment portfolio by exposures to varying product categories, hence concentration of risk is minimised. At the year end the financial assets at fair value through profit or loss, which are subject to market price risk, are as follows:

As at 30 June	2018		2017	
	Fair Value	% of net assets	Fair Value	% of net assets
	<u>GBP</u>		<u>GBP</u>	
Equities	24,353,588	96.17	27,129,195	98.07

The Cell's market risk is affected by three main components: changes in actual market prices, interest rate and foreign currency exchange rates movements. Interest rate and foreign currency movements are covered in notes 2.3 and 2.5 respectively. If the market indices increased or decreased by 10% with all other variables held constant, the increase or decrease respectively in net assets attributable to holders of participating redeemable shares would amount to:

As at 30 June	2018	2017
	Change in fair value	Change in fair value
	<u>GBP</u>	<u>GBP</u>
Equities	2,435,359	2,712,920

2.3 Interest rate risk

The Cell's interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short-term market interest rates.

The table below summarises the Cell's exposure to interest rate risk. It includes the Cell's assets and trading liabilities at fair values, all of which have contractual re-pricing or maturity dates within one month.

As at 30 June	2018	2017
	<u>GBP</u>	<u>GBP</u>
	Net financial assets on which no interest is paid	24,215,280
Net floating rate financial assets	1,108,761	721,520

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Notes to the Financial Statements

2. Financial risk management (continued)

2.3 Interest rate risk (continued)

Should interest rates have increased by 100 basis points with all other variables remaining constant, the increase in the net assets attributable to participating redeemable shareholders would amount to approximately:

As at 30 June	2018	2017
	<u>GBP</u>	<u>GBP</u>
Net floating rate financial assets	11,088	7,215

A decrease of 50 basis points would have a minimal effect as interest received at period end was immaterial.

2.4 Cash flow risk

The Cell holds a significant amount of cash and cash equivalents that expose the Cell to cash flow interest rate risk. The risk exposure here is deemed minimal.

2.5 Currency risk

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets, including investments, denominated in currencies other than the Pound Sterling, the functional currency, and therefore it is exposed to currency risk. The exposures are based on the currencies of the underlying assets in each Cell. Where the Cell invests via Collective Investment Funds, the funds are treated as a single asset with its currency of exposure being assumed to be its reporting currency.

The table below summarises the Cell's exposure to currency risks:

As at 30 June	2018	2017
	<u>GBP</u>	<u>GBP</u>
AUD exposure	841,221	-
EUR exposure	24,528	-
HKD exposure	966,796	-
MXN exposure	131,225	-
NOK exposure	-	328,581
SGD exposure	238,206	476,793
USD exposure	14,104,643	15,987,644

In accordance with the Cell's policy, the Investment Manager monitors the Cell's currency position on a regular basis, and the Board of Directors reviews it periodically. The Cell has the ability to enter into forward foreign exchange contracts in an attempt to mitigate any significant currency risk, however to date the Investment Manager and Board of Directors have deemed that such contracts have not been necessary.

Should the Cell's functional currency have strengthened, or weakened, by 5% against other currencies to which it is exposed and all other variables, including the price of all investments, had held constant, the net asset attributable to participating redeemable shareholders would have increased, or decreased, as follows:

As at 30 June	2018	2017
	<u>GBP</u>	<u>GBP</u>
AUD exposure	42,061	-
EUR exposure	1,226	-
HKD exposure	48,340	-
MXN exposure	6,561	-
NOK exposure	-	16,429
SGD exposure	11,910	23,840
USD exposure	705,232	799,382

2.6 Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

There is a risk that an investee company may be unable to satisfy a valid redemption request made by a Cell. The Directors consider that the Investment Manager mitigates this risk by way of its investment process, as described in note 2.2.

All transactions in listed securities are settled/paid for upon delivery using approved brokers. Delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. Given the relatively short settlement period, and the high credit quality of the brokers used, the risk here is considered to be minimal.

The Cell manages its exposure to credit risk associated with cash deposits by selecting Northern Trust (Guernsey) Limited as the counterparty to hold all cash deposits for the Cell. The Northern Trust Company is a wholly owned subsidiary of the Northern Trust Corporation. The credit rating for Northern Trust Corporation from Standard and Poor's is A+. The credit rating from Moody's is A2.

The Cell's maximum exposure to credit risk is the carrying value of the assets on the Statement of Financial Position.

2.7 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with its financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption processes which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradable and have reported no warnings regarding their ability to process redemptions as normal.

The Cell has the ability to borrow to meet short term liquidity requirements, however to date the Cell has not entered into such arrangement.

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Notes to the Financial Statements

2. Financial risk management (continued)

2.7 Liquidity risk (continued)

The table below analyses the Cell's financial assets and financial liabilities into relevant maturity groupings based on the remaining period at the Statement of Financial Position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is not significant.

	2018			2017		
	Less than 1 month	Between 1 and 12 months	Total	Less than 1 month	Between 1 and 12 months	Total
	GBP	GBP	GBP	GBP	GBP	GBP
Financial assets at fair value through profit or loss	24,353,588	-	24,353,588	27,129,195	-	27,129,195
Cash and cash equivalents	1,108,761	-	1,108,761	814,707	-	814,707
Dividend receivable	27,631	-	27,631	118,120	-	118,120
Other receivables	487	-	487	458	-	458
Fair value of derivative financial instruments	-	-	-	-	(21)	(21)
Bank overdraft	-	-	-	(93,187)	-	(93,187)
Securities purchased payable	(129,334)	-	(129,334)	(274,298)	-	(274,298)
Other payables	(37,092)	-	(37,092)	(38,051)	-	(38,051)
Net assets attributable to participating redeemable shares	(25,324,041)	-	(25,324,041)	(27,656,923)	-	(27,656,923)
Net liquidity position	-	-	-	21	(21)	-

Participating redeemable shares are redeemed on demand at the holder's option. However the Board of Directors does not envisage that the contractual maturity disclosed in the table on the previous page will be representative of the actual cash flows, as holders of these instruments typically retain them for the medium to long term.

2.8 Management of capital

The Board, with the assistance of the Investment Manager, manages the capital of the Cell in accordance with the investment objectives and policies. The overall strategy of the Cell remains unchanged.

The Cell has no externally imposed capital requirements.

2.9 Fair value disclosure

In the opinion of the Directors, there is no material difference between the net asset values of the underlying assets and fair values of the financial assets and liabilities of the Cell.

3. Critical accounting estimates and judgements

The fair value of investments has been based on the listed market bid prices, or prices supplied by the fund administrators of the Cell's underlying investments.

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

The fair value of investments in investee funds that are not quoted in an active market is determined primarily by reference to the latest available redemption price of such units for each investee fund, as determined by the administrator of such investee fund. The Investment Manager may make adjustments to the reported net asset value of various investee funds based on considerations such as:

- the liquidity of the investee fund or its underlying investments;
- the value date of the net asset value provided;
- any restrictions on redemptions; and
- the basis of accounting and, in instances where the basis of accounting is other than fair value, fair valuation information provided by the investee fund's advisors.

The prices are reviewed by the Investment Manager on a periodic basis.

4. Portfolio analysis

The Cell's portfolio is organised by focusing on the type of security held and then secondarily by geographical analysis based on the location of the investment.

The Cell operates using the main sector types which are disclosed in note 2.2 and the following main geographical areas:

	2018	2017
	GBP	GBP
Australia	840,954	328,582
Cayman Islands	917,327	-
Europe	2,154,013	2,727,713
Hong Kong	956,351	-
Mexico	127,317	-
Singapore	234,338	-
United Kingdom	8,041,566	12,131,071
United States of America	11,081,722	11,941,829
	24,353,588	27,129,195

The geographical segment for listed non-monetary financial assets is considered to be the place of primary listing and for non-listed financial assets where the underlying investment is domiciled.

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Notes to the Financial Statements

5. Financial assets at fair value through profit or loss

	2018	2017
	GBP	GBP
Financial assets at fair value through profit or loss:		
Equities	24,353,588	27,129,195
Total financial assets at fair value through profit or loss	24,353,588	27,129,195
	For the year ended 30.06.18	For the year ended 30.06.17
Movement on financial assets at fair value through profit or loss		
Fair value of financial assets at the beginning of the year	27,129,195	11,506,353
Purchases of financial assets	24,650,420	27,949,951
Sales of financial assets	(28,099,200)	(15,339,618)
Realised gains on sale of financial assets	1,945,720	1,963,865
Movement in unrealised gains on revaluation of financial assets	(1,272,547)	1,048,644
Fair value of financial assets at the end of the year	24,353,588	27,129,195
Comprising:		
Cost at the end of the year	23,412,477	24,915,537
Unrealised gains at the end of the year	941,111	2,213,658
	24,353,588	27,129,195

IFRS 13 requires the Cell to classify fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy has the following levels:

- Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 – inputs other than quoted prices included with Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy, within which the fair value measurement is categorised in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Board. The Board considers observable market data that is readily available, readily distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market.

The investments classified as Level 1 consist of financial assets that are actively traded with fair values readily available from recognised exchanges. The Level 1 hierarchy may also include investments in funds that are priced by the underlying administrator where the Company considers it to be the most advantageous market and would enter into transactions based on those prices.

The investments classified as Level 2 are investments in funds that are actively traded and priced less frequently than monthly but not greater than quarterly for which fair values are obtained from the underlying administrator or fund manager.

The investments classified as Level 3 are investments that are illiquid investments and investments that are traded but priced less frequently than quarterly.

The following tables present the Cell's financial assets and financial liabilities measured at fair value by level within the valuation hierarchy as of 30 June 2018 and 30 June 2017.

30 June 2018	Level 1	Level 2	Level 3	Total
	GBP	GBP	GBP	GBP
Financial assets at fair value through profit or loss				
Equities	24,281,470	-	72,118	24,353,588
30 June 2017				
	Level 1	Level 2	Level 3	Total
	GBP	GBP	GBP	GBP
Financial assets at fair value through profit or loss				
Equities	27,129,195	-	-	27,129,195

There were no movements or reclassifications of investments within the levels of the fair value hierarchy during the year ended 30 June 2018 and period ended 30 June 2017.

Assets and liabilities not carried at fair value but for which fair value is disclosed

The following tables analyse within the fair value hierarchy the Cell's assets and liabilities (by class) not measured at fair value at 30 June 2018 and 30 June 2017 but for which fair value is disclosed.

30 June 2018	Level 1	Level 2	Level 3	Total
	GBP	GBP	GBP	GBP
Assets				
Cash and cash equivalents	1,108,761	-	-	1,108,761
Dividend receivable	-	27,631	-	27,631
Other receivables	-	552	-	552
Total	1,108,761	28,183	-	1,136,944
Liabilities				
Securities purchased payable	-	129,334	-	129,334
Other payables	-	37,092	-	37,092
Net assets attributable to holders of participating redeemable shares	-	25,324,041	-	25,324,041
Total	-	25,490,467	-	25,490,467

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Notes to the Financial Statements

5. Financial assets at fair value through profit or loss (continued)

Assets and liabilities not carried at fair value but for which fair value is disclosed (continued)

30 June 2017	Level 1	Level 2	Level 3	Total
Assets	GBP	GBP	GBP	GBP
Cash and cash equivalents	814,707	-	-	814,707
Dividend receivable	-	118,120	-	118,120
Other receivables	-	523	-	523
Total	814,707	118,643	-	933,350
Liabilities				
Fair value of derivative financial instruments	-	21	-	21
Bank overdraft	93,187	-	-	93,187
Securities purchased payable	-	274,298	-	274,298
Other payables	-	38,051	-	38,051
Net assets attributable to holders of participating redeemable shares	-	27,656,923	-	27,656,923
Total	93,187	27,969,293	-	28,062,480

6. Cash and cash equivalents

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise the following balances with original maturity of less than 90 days:

	2018	2017
	GBP	GBP
Cash at bank	1,108,761	814,707
Bank overdraft	-	(93,187)
	1,108,761	721,520

7. Derivative Financial Instruments

30 June 2018

No spot foreign currency contracts were open at 30 June 2018.

30 June 2017

Spot foreign currency contracts designated as at fair value through profit or loss:

Expiration	Underlying	Notional amount of contracts outstanding	2017 Fair value (liability)/asset
3 July 2017	Foreign currency (purchase of GBP)	GBP 107,765	(107,786)
3 July 2017	Foreign currency (sale of GBP)	GBP 107,765	107,765

8. Other receivables

	2018	2017
	GBP	GBP
Prepayments	476	446
Management shares receivable	65	65
Other receivables	11	12
	552	523

9. Other payables

	2018	2017
	GBP	GBP
Audit fee payable	8,742	8,398
Custodian fee payable	471	509
Investment management fee payable	18,053	20,095
Management fee payable	6,055	7,350
Other payables	3,771	1,699
	37,092	38,051

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Notes to the Financial Statements

10. Share capital

Each Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

Management Shares in Issue	30.06.18		30.06.17
	USD	GBP	GBP
Management shares	100	65	65

Participating Redeemable Shares in Issue	For the year ended 30.06.18		For the year ended 30.06.17	
	Class A	Class B	Class A	Class B
Balance at the start of the year	6,449,819	18,960,093	2,602,100	11,054,674
Issue of participating redeemable shares	171,883	1,207,862	3,924,443	8,309,526
Redemption of participating redeemable shares	(1,841,875)	(2,243,954)	(76,724)	(404,107)
Balance at the end of the year	4,779,827	17,924,001	6,449,819	18,960,093

Participating Redeemable Share Capital Account	For the year ended 30.06.18		For the year ended 30.06.17	
	Class A GBP	Class B GBP	Class A GBP	Class B GBP
Balance at the start of the year	7,595,956	15,577,196	2,672,994	8,221,284
Issue of participating redeemable shares	235,664	1,186,416	5,021,957	7,734,788
Redemption of participating redeemable shares	(2,524,470)	(2,196,612)	(98,995)	(378,876)
Balance at the end of the year	5,307,150	14,567,000	7,595,956	15,577,196

11. Net asset value per participating redeemable share

As at 30 June	2018			2017		
	NAV per share	Net assets attributable	Shares in issue	NAV per share	Net assets attributable	Shares in issue
	2018	2018	2018	2017	2017	2017
	GBP	GBP		GBP	GBP	
Class A (GBP class)	1.43	6,855,526	4,779,827	1.38	8,887,644	6,449,819
Class B (USD class)	1.03	18,468,515	17,924,001	0.99	18,769,279	18,960,093
		25,324,041	22,703,828		27,656,923	25,409,912

12. Dividends payable to participating redeemable shareholders

No dividends were paid during the year (2017: Nil) and the Board does not intend to pay any dividends. All available income will be reinvested.

13. Related-party transactions

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

13.1 Management and Administration fee

The Cell is managed by Momentum Wealth International Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement in place.

The Manager and the Administrator is entitled to receive the following Management and Administration fee, chargeable on a sliding scale, payable monthly in arrears, based on the current valuation and subject to a minimum annual fee of USD22,000 or currency equivalent per Cell in respect of all share classes.

Fee - % of NAV per annum	Cell NAV
0.30%	Up to GBP20m
0.25%	From GBP20m to GBP40m
0.20%	Over GBP40m

Management and Administration fee charged during the year/period and accrued at year/period end:

	For the year ended 30.06.18	For the year ended 30.06.17
	GBP	GBP
Charged during the year	73,627	69,320
Accrued at year end	6,055	7,350

13.2 Investment Management fee & Sub-Investment Management Fee

The Manager has appointed an Investment Manager, Momentum Global Investment Management Limited, a UK registered company, to manage the investment portfolio of the Cell. The Investment Manager is entitled to receive the following Investment Management fee, chargeable on a sliding scale, payable monthly in arrears, based on the current valuation and subject to a minimum annual fee of USD40,000 or currency equivalent per Cell in respect of all share classes on a pro rata basis. This minimum excludes the Sub-Investment Management fee payable to the Sub-Investment Manager who is entitled to receive a fee equal to 0.75% of the NAV of the Cell per annum (the "Sub-Investment Management Fee"), which will be paid out of the fee received by the Investment Manager, and relates to the net portion of Investment Management Fee of 0.10% only.

Fee - % of NAV per annum	Cell NAV
0.85%	Up to GBP20m
0.83%	From GBP20m to GBP40m
0.80%	Over GBP40m

Momentum Mutual Fund ICC Limited
Annual Report and Audited Financial Statements for the year ended 30 June 2018

Credo Global Cell

Notes to the Financial Statements

13. Related-party transactions (continued)

13.2 Investment Management fee (continued)

Investment Management fee charged during the year/period and accrued at year/period end:

	For the year ended 30.06.18	For the year ended 30.06.17
	<u>GBP</u>	<u>GBP</u>
Charged during the year	217,418	182,953
Accrued at year end	18,053	20,095

13.3 Custodian fee

Northern Trust (Guernsey) Limited was appointed to provide custodian services. The Custodian will be paid a safekeeping fee on a market by market basis between 0.01% and 0.80%. The Custodian fee will be subject to a minimum fee of USD8,000 and will be borne by the Classes on a pro rata basis per annum.

Custodian fee charged during the year and accrued at year end:

	2018	2017
	<u>GBP</u>	<u>GBP</u>
Charged during the year	6,719	13,319
Accrued at year end	471	509

13.4 Distribution Partner fee

Pursuant to the Distribution Agreement dated 12 November 2015, the Directors and the Manager have appointed Credo Capital Plc as Distribution Partner. The Distribution Partner shall have the exclusive rights to promote and market the Cell and shall provide its services in the promotion, marketing and advertising of the Cell.

Pursuant to the Supplemental Cell Prospectus dated 09 August 2017, the Distribution Partner will not be paid a fee.

13.5 Sub-Investment Management Fee

The Investment Manager has appointed Credo Capital Plc (the "Sub-Investment Manager"), a public limited company incorporated in the United Kingdom to act as Sub-Investment Manager of the Cell.

Pursuant to the Sub-Investment Management Agreement, the Sub-Investment Manager is entitled to receive a fee equal to 0.75% of the NAV of the cell per annum (the "Sub-Investment Management fee"), which will be paid out of the fee received by the Investment Manager. The Sub-Investment Management fee will accrue as at each valuation point, based on the current valuation and is payable monthly in arrears.

13.6 Board of Directors' remuneration

The Directors' fees in respect of each Cell shall not exceed USD20,000 or currency equivalent in any twelve month period. In addition, the Directors shall be entitled to be repaid for all reasonable out of pocket expenses properly incurred by them in the performance of their duties to the Cell. Such fees and expenses shall be paid out of the assets of each Cell alone and not from the cellular assets of other cells of the Company or assets of the Company itself.

The Directors waived their right to a fee during the year (2017: Nil).

14. Ultimate controlling party

In the opinion of the Directors, on the basis of the shareholdings advised to them, the Cell has no ultimate controlling party.

15. Reconciliation of published valuation to financial statements

	2018	2017
	<u>GBP</u>	<u>GBP</u>
Net assets per financial statements	25,324,041	27,656,923
Adjustment in value of assets at financial assets at fair value through profit or loss	-	-
Other receivable	(11)	(12)
Write off set up cost	2,953	4,056
Net assets per published valuation	25,326,983	27,660,967
NAV per Class A per published valuation	1.43	1.38
NAV per Class B per published valuation	1.03	0.99
NAV per Class A per financial statements	1.43	1.38
NAV per Class B per financial statements	1.03	0.99

16. Subsequent events

These financial statements were approved for issuance by the Board on 5 December 2018. Subsequent events have been evaluated until this date.

On 8 August 2018, amendments were made to the Supplemental Cell Prospectus of the Cell, implementing the following changes with effect from that date:

- The reference to South African FSB notice 569, has been updated to "FSB Board Notice 90 of 2014, Chapter VI"
- The reference to Financial Services Board, has been updated to "Financial Sector Conduct Authority."

On 19 September 2018, amendments were made to the Supplemental Cell Prospectus of the Cell, implementing the following change with effect from that date:

Reference to the sub-investment manager as Credo Capital plc, a public limited company incorporated in the United Kingdom was changed to Credo Capital Ltd, a limited company incorporated in the United Kingdom.

No other significant subsequent events have occurred in respect of the Cell that are considered material to the understanding of these audited financial statements.